Alcohol withdrawal in a patient with significant liver disease
A 45-year-old oil-field supervisor is admitted with epigastric pain and vomiting; lipase is three times the upper limit of normal. He drinks approximately 700–1000 mL of whisky daily and has done so for 15 years, with morning tremor and a withdrawal seizure at home 2 days ago. On arrival he is sweaty, tremulous, disoriented to time, pulse 118, BP 168/102, temperature 37.6°C, and CIWA-Ar is 18. Bloods show platelets 78 ×10^9/L, INR 1.4, AST 180 U/L, ALT 95 U/L, GGT 610 U/L, bilirubin 38 µmol/L, albumin 30 g/L, creatinine 110 µmol/L, potassium 3.1 mmol/L, magnesium 0.62 mmol/L and glucose 5.4 mmol/L. He has had no benzodiazepines. He wants to stop drinking and asks about medication to prevent relapse; his wife reports previous attempts without follow-up.
1. Set out your immediate management, including the choice and dosing of benzodiazepine, thiamine and electrolyte correction, justifying each decision in the context of his liver disease.
Read the worked answer
This is moderate-to-severe alcohol withdrawal (CIWA-Ar 18) with a recent withdrawal seizure and early features of delirium tremens - tachycardia, hypertension, sweating and disorientation. He needs admission, not discharge.
Benzodiazepines are first-line, given symptom-triggered with a validated scale (or as a fixed reducing regimen if delirium tremens is established). Because of significant liver disease (thrombocytopenia, raised INR and bilirubin, low albumin), lorazepam is preferred: it undergoes glucuronidation, has no active metabolites and does not accumulate in hepatic impairment. Give 2 mg orally or intravenously every 1–2 hours until CIWA-Ar is below 8, then as needed. Diazepam is acceptable if hepatic function is preserved but accumulates; avoid chlordiazepoxide in severe liver disease. Phenobarbital is a rescue option for refractory delirium tremens in critical care, not on a general ward.
Thiamine 100–200 mg IV (or 500 mg IV three times daily if Wernicke's encephalopathy is suspected) must be given before any glucose-containing fluid. Correct magnesium (0.62 mmol/L is low - give 2 g IV magnesium sulphate) and potassium, and monitor for arrhythmia.
Nursing: quiet, well-lit environment, frequent CIWA-Ar, fluid balance, seizure precautions, and monitoring for Wernicke's triad of confusion, ophthalmoplegia and ataxia.
2. Which relapse-prevention medication would you choose given his liver enzymes, and how do the alternatives compare?
Read the worked answer
Acamprosate is the best choice here. It is renally excreted and not hepatotoxic, so it is safe with his liver function; the dose is 666 mg three times daily, adjusted for renal impairment - check creatinine, which is borderline at 110 µmol/L. It reduces relapse in abstinent patients and should be combined with psychosocial support.
Naltrexone is effective but hepatotoxic and should be avoided when transaminases exceed roughly 3–5 times the upper limit of normal or in acute hepatitis. His AST of 180 and ALT of 95 are elevated, so naltrexone is relatively contraindicated until the liver enzymes settle and the pancreatitis resolves. Disulfiram is absolutely inappropriate: it is hepatotoxic and can precipitate a severe reaction with any alcohol, risking fulminant hepatitis in a patient with established liver disease.
Nalmefene is an opioid antagonist with similar hepatic caution. Gabapentin may help mild withdrawal and sleep but is off-label and has misuse potential; baclofen has some evidence in alcohol dependence and may be considered in liver disease, but the data are weaker and sedation is a risk.
Whatever is chosen, add motivational interviewing, CBT or a structured relapse-prevention programme, treat the pancreatitis, and arrange addiction-liaison follow-up. Medication alone will not work without engagement.
3. Assess his risk of complicated withdrawal and outline the discharge and safety plan.
Read the worked answer
Risk: a prior withdrawal seizure increases the risk of delirium tremens several-fold, and untreated delirium tremens carries mortality of roughly 5–15%. Additional risks here are heavy long-standing intake, abnormal liver function, thrombocytopenia, hypokalaemia, hypomagnesaemia and pancreatitis. He should remain admitted until CIWA-Ar has been below 8 for 24 hours, he is eating and hydrated, and he has been seizure-free; he must not be discharged from the emergency department.
Discharge plan: addiction-liaison referral before discharge, acamprosate with adherence support, GP follow-up within a week, keyworker and mutual-help groups, and screening for depression, anxiety and suicide risk - all common in this population and easy to overlook.
Give a written relapse plan and explain that continued drinking will cause recurrent pancreatitis and progressive liver disease. Discuss driving, employment and occupational health, since his job may involve access to alcohol and safety-sensitive work. Involve his wife, offer family support, and document the conversation. Warn him that abrupt unsupervised cessation at home is dangerous and that he should seek help early if withdrawal symptoms begin.